India Markets open in 14 mins

Granules gets USFDA nod for postpartum haemorrhage prevention drug

Faizan Javed
1 / 1

Suven Life gets product patents from New Zealand, Norway

These patents are valid till 2034 and 2027, respectively, the company said in a BSE filing.

Drug firm Granules India today said its subsidiary has received approval from the US health regulator for Methylergonovine tablets, used for the prevention and control of postpartum haemorrhage.

In a filing to BSE, Granules India said "the U S Food and Drug Administration (USFDA) has approved its abbreviated new drug applications (ANDA) for Methylergonovine 0.2 mg tablets. The ANDA was filed by Granules Pharmaceuticals Inc., a wholly owned subsidiary of Granules India Ltd".

The approved product is the bioequivalent to the reference listed drug product Methergine 0.2 mg, it added.

Shares of Granules India were trading at Rs 105.40 per scrip on BSE, up 8.94 per cent.